Eikonizo Therapeutics $2.00 million Financing. Janice Kranz Published Apr 17 D Filing

April 17, 2018 - By Hazel Jackson

Eikonizo Therapeutics Financing

Eikonizo Therapeutics, Inc., Corporation just filed form D because of $2.00 million equity financing. This is a new filing. Eikonizo Therapeutics was able to finance itself with $2.00 million. That is 100.00 % of the fundraising. The total offering amount was $2.00 million. The form was filed on 2018-04-17. The reason for the financing was: unspecified.

Eikonizo Therapeutics is based in Massachusetts. The firm’s business is Other Health Care. The form D was signed by Janice Kranz Chief Executive Officer. The company was incorporated in 2017. The filler’s address is: 996 Hale Street, Beverly, Ma, Massachusetts, 01915. Janice Kranz is the related person in the form and it has address: 996 Hale Street, C/O Eikonizo Therapeutics, Inc., Beverly, Ma, Massachusetts, 01915. Link to Eikonizo Therapeutics Filing: 000173575618000001.

Analysis of Eikonizo Therapeutics Offering

On average, startups in the Other Health Care sector, sell 68.60 % of the total offering amount. Eikonizo Therapeutics sold 100.00 % of the offering. Could this mean that the trust in Eikonizo Therapeutics is high? The average fundraising amount for companies in the Other Health Care industry is $1.16 million. The total amount raised is 72.41 % bigger than the average for companies in the Other Health Care sector. The minimum investment for this offering was set at $0. If you know more about the reasons for the fundraising, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Eikonizo Therapeutics Also

The Form D signed by Janice Kranz might help Eikonizo Therapeutics, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: